


2023 Funded Research

Cure Alzheimer's Fund spent \$27.8 million to support our research program that included grants for 114 research projects across four research areas of focus. Scan the QR code to read about 2023 research projects or visit us online at bit.ly/2023_research.



Number of New Investigators and Projects

	Number	% of Total
New Named Investigators	35	24%
New Projects	43	38%
New Institutions	5	9%

* Excludes research materials and scientific meeting spending.

Project/Researcher	Distribution Amount
FOUNDATIONAL RESEARCH	
GENETIC RISK FACTORS	
Analytical and Statistical Tools for Sequence Analysis for Alzheimer's Disease Christoph Lange, Ph.D., Harvard T.H. Chan School of Public Health	\$220,071
Genetic Ancestry-Specific Risk Estimation of Alzheimer's Disease in the APOE Region Christoph Lange, Ph.D., Harvard T.H. Chan School of Public Health	\$40,250
Genomic Variant Calling and Data Management for the Cure Alzheimer's Fund Alzheimer's Genome Project™ Winston Hide, Ph.D., Beth Israel Deaconess Medical Center; Harvard Medical School	\$118,450
The Alzheimer's Genome Project™ Rudolph E. Tanzi, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$1,955,000
BIOMARKERS, DIAGNOSTICS, AND STUDIES OF RISK AND RESILIENCE	
Adding Genomics and Methyloomics to Personalized Disease Prediction for Alzheimer's Disease (EPIC4AD) Lars Bertram, M.D., University of Lübeck, Germany Christina M. Lill, M.D., M.Sc., University of Münster, Germany; Imperial College London, England	\$116,684
Cerebrospinal Fluid Neuroinflammatory Signature in Alzheimer's Disease and Related Proteopathies Mathias Jucker, Ph.D., University of Tübingen, Germany Stephan Kaeser, Ph.D., University of Tübingen, Germany Stefan Lichtenthaler, Ph.D., German Center for Neurodegenerative Diseases (DZNE); Technische Universität München (TUM), Germany	\$180,550
Characterization of Alzheimer's Disease Molecular Biomarker Profiles Throughout the Pathobiological Continuum Krista L. Moulder, Ph.D., Washington University School of Medicine in St. Louis	\$113,655
Characterization of the Longitudinal Trajectories of the Synaptic Blood Marker Beta-Synuclein During Alzheimer's Disease Pathogenesis and Improvement of the Measurement Procedure Patrick Oeckl, Ph.D., German Center for Neurodegenerative Diseases (DZNE), Germany Markus Otto, M.D., Martin-Luther-University Halle-Wittenberg, Germany	\$144,325
Identification and Validation of Plasma-Based Lipid Biomarkers for Early Alzheimer's Disease in the Unique, Primarily Hispanic, South Texas Population Xianlin Han, Ph.D., The University of Texas Health Science Center at San Antonio Juan Pablo Palavicini, Ph.D., The University of Texas Health Science Center at San Antonio Tiffany F. Kautz, Ph.D., The University of Texas Health Science Center at San Antonio Bernard Fongang, Ph.D., The University of Texas Health Science Center at San Antonio	\$201,250

2023 FUNDED RESEARCH (CONTINUED)

Project/Researcher	Distribution Amount
Precision Medicine Prediction Model for Alzheimer's Disease Using Cooperative Learning Approaches for Multi-Omic Data Christoph Lange, Ph.D., Harvard T.H. Chan School of Public Health	\$150,000
Understanding Human Brain Resilience to Alzheimer's Pathology Teresa Gomez-Isla, M.D., Massachusetts General Hospital; Harvard Medical School	\$300,000
Utility of Blood-Based Markers for Predicting Amyloid-Related Imaging Abnormalities and Their Course in Mild Cognitive Impairment and Alzheimer's Disease Subjects Undergoing Routine Clinical Treatment with Amyloid-Directed Antibodies Murali Doraiswamy, M.B.B.S., Duke University School of Medicine	\$229,994
BIOLOGICAL RESEARCH MATERIALS: NEW ANIMAL AND CELLULAR MODELS, AND HUMAN SAMPLES	
Characterization and Validation of Two Recently Created Sheep Models of Alzheimer's Disease in Preparation for Use as a Preclinical Pharmaceutical Testing Model Russell G. Snell, Ph.D., University of Auckland, New Zealand Natasha McKean, Ph.D., University of Auckland, New Zealand	\$200,933
Genes to Therapies™ (G2T) Research Models and Materials Taconic Biosciences	\$496,283
Dissecting Alzheimer's Disease Phenotypes in Directly Reprogrammed Patient-Derived Neurons Andrew S. Yoo, Ph.D., Washington University School of Medicine in St. Louis	\$201,250
Growth, Characterization and Distribution of a Neurodegenerative Disease-Focused Fibroblast/iPS Cell Bank to Support Molecular Models of Patient-Specific Variation with Validation in Matched Donated Brain Tissues Derek H. Oakley, M.D., Ph.D., Massachusetts General Hospital; Harvard Medical School	\$201,250
Influence of Plaque Vicinity on Microglial and Astrocyte Gene Expression; Role of Human Tau and TREM2 Frances Edwards, Ph.D., University College London, England John Hardy, Ph.D., University College London, England	\$172,369
Multidisciplinary Phenotyping of a Novel Humanized LOAD Mouse Model Giuseppina Tesco, M.D., Ph.D., Tufts University School of Medicine	\$201,250
TRANSLATIONAL RESEARCH	
STUDIES OF NOVEL ALZHEIMER'S DISEASE GENES	
ABCA7 Loss of Function in Aging and Alzheimer's Disease Takahisa Kanekiyo, M.D., Ph.D., Mayo Clinic, Jacksonville	\$201,250
Exploring the Therapeutic Potential of Clusterin in a Preclinical Model of Alzheimer's Disease Alban Gaultier, Ph.D., University of Virginia	\$201,250
Role of Ras and Rab Interactor 3 (RIN3) and Bridging Integrator 1(BIN1) Interaction in the Neurons for Alzheimer's Disease Development Raja Bhattacharyya, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$201,250
The Impact of Mutations in the Ligand-Binding Domain of CD33 on Alzheimer's Disease Pathogenesis Ana Griciuc, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$125,000
STUDIES OF AMYLOID PRECURSOR PROTEIN AND AMYLOID BETA	
APP Gene Dose-Mediated Dysregulation of the Endolysosomal Network Acts to Compromise Synaptic Structure and Function Leading to Alzheimer's Disease in Down Syndrome William C. Mobley, M.D., Ph.D., University of California, San Diego	\$230,000
STUDIES OF TAU	
Alzheimer's Disease Tau Consortium: How Do Soluble Tau Species Replicate Bradley T. Hyman, M.D., Ph.D., Massachusetts General Hospital; Harvard Medical School	\$287,169
Alzheimer's Disease Tau Consortium: Impact of Tau Mutations and Amyloid Beta on Tau Post-Translational Modifications and Conformation Karen E. Duff, Ph.D., University College London, England	\$344,993

2023 FUNDED RESEARCH (CONTINUED)

Project/Researcher	Distribution Amount
Alzheimer's Disease Tau Consortium: Role of VCP/p97 in Tau Prion Replication Marc I. Diamond, M.D., University of Texas Southwestern Medical Center	\$287,000
Alzheimer's Disease Tau Consortium: The Role of Amyloid Beta-Induced Membrane Damage in Tau Pathology Katherine Sadleir, Ph.D., Northwestern University Feinberg School of Medicine Robert J. Vassar, Ph.D., Northwestern University Feinberg School of Medicine	\$286,448
Characterization of Tau Pathology Heterogeneity Across the Alzheimer's Disease Spectrum Oskar Hansson, M.D., Ph.D., Lund University, Sweden Rik Ossenkoppele, Ph.D., Amsterdam University Medical Center, The Netherlands; Lund University, Sweden	\$201,250
Identifying Mediators of Tau-Mediated Neuronal Necroptosis Using an Innovative In Vivo CRISPR Screen Bart De Strooper, M.D., Ph.D., KU Leuven, Belgium; University College London, England Sriram Balusu, Ph.D., KU Leuven, Belgium	\$230,000
Multomics Characterization of Tau Pathology Onset and Its Relationship with Amyloid in the Human Hippocampus Inma Cobos, M.D., Ph.D., Stanford University	\$201,250
Regional Variability of Pathology-Associated Properties of Tau in Posterior Cortical Atrophy Bradley T. Hyman, M.D., Ph.D., Massachusetts General Hospital; Harvard Medical School John R. Dickson, M.D., Ph.D., Massachusetts General Hospital; Harvard Medical School	\$172,000
RNA as a Determinant of Tau Seeding Marc I. Diamond, M.D., University of Texas Southwestern Medical Center	\$230,000
Targeting Microglial TSG101 for Synaptic Protection and Cognitive Enhancement in Alzheimer's Disease Seiko Ikezu, M.D., Mayo Clinic, Jacksonville Tsuneya Ikezu, M.D., Ph.D., Mayo Clinic, Jacksonville	\$172,500
Tau-Induced Postsynaptic Dysfunction in Tauopathy Models Karin Hochrainer, Ph.D., Weill Cornell Medicine Costantino Iadecola, M.D., Weill Cornell Medicine	\$201,250
Toxic Effects of Extracellular Tau Oligomers on Neurons George S. Bloom, Ph.D., University of Virginia	\$192,020
STUDIES OF APOLIPOPROTEIN E (APOE)	
Fleming APOE Consortium: APOE Genotype-Specific Effects of Human Young Plasma on Cerebrovasculature and Alzheimer's Disease Pathology Guojun Bu, Ph.D., Hong Kong University of Science and Technology	\$287,500
Fleming APOE Consortium: APOE4-Mediated Dysfunction of CD8 T-Cell-Microglia Crosstalk in Alzheimer's Disease Oleg Butovsky, Ph.D., Brigham and Women's Hospital; Harvard Medical School	\$287,500
Fleming APOE Consortium: Modulation of Selective Neuronal Vulnerability in Alzheimer's Disease by Apolipoprotein E Jean-Pierre Roussarie, Ph.D., Boston University	\$287,500
Fleming APOE Consortium: Role of APOE Isoforms in Immune Responses in a Model of Tauopathy David M. Holtzman, M.D., Washington University School of Medicine in St. Louis	\$345,000
Cellular and Molecular Studies of Apolipoprotein E Regulation of Blood-Brain Barrier, Synaptic and Neuronal Functions and Protection Strategies in Mouse Models With and Without Alzheimer's Pathology Berislav V. Zlokovic, M.D., Ph.D., University of Southern California	\$250,000
Elucidating the Protective Effects of APOE2 in the Presence of APOE4 Gene Allele in Animal Models Na Zhao, M.D., Ph.D., Mayo Clinic, Jacksonville Yingxue Ren, Ph.D., Mayo Clinic, Jacksonville	\$201,250
Investigating Lysosomal Mechanisms of Risk and Resilience in Alzheimer's Disease Joel Blanchard, Ph.D., Icahn School of Medicine at Mount Sinai	\$201,250
Mitochondrial Alzheimer's Risk Factors Control APOE Expression and Secretion Victor Faundez, M.D., Ph.D., Emory University	\$201,250

2023 FUNDED RESEARCH (CONTINUED)

Project/Researcher	Distribution Amount
Neuroproteasomes Mechanistically Connect APOE Isoforms to Endogenous Tau Aggregation Kapil V. Ramachandran, Ph.D., Columbia University	\$201,501
Protection Against APOE4 with Longevity-Promoting Interventions Christian Pike, Ph.D., University of Southern California Caleb E. Finch, Ph.D., University of Southern California B�er�enice A. Benayoun, Ph.D., University of Southern California	\$234,709
STUDIES OF THE IMMUNE RESPONSE IN ALZHEIMER'S DISEASE	
CIRCUITS: Dissecting Microglial State Dynamics in Alzheimer's Disease Li-Huei Tsai, Ph.D., Massachusetts Institute of Technology; Broad Institute	\$300,000
Neuroimmune Consortium: Effects of Peripheral Inflammation on Myeloid Cell Function in Alzheimer's Disease Beth Stevens, Ph.D., Boston Children's Hospital; Harvard Medical School; Broad Institute	\$344,085
Neuroimmune Consortium: Examining the Impact of Peripherally Derived Human Macrophages in Alzheimer's Disease Pathogenesis Mathew Blurton-Jones, Ph.D., University of California, Irvine	\$287,493
Neuroimmune Consortium: Mechanisms Mediating Microglia Sensing of Peripheral Inflammation Christopher K. Glass, M.D., Ph.D., University of California, San Diego	\$287,500
A New Model of Microglia Genetic Perturbation in Vivo to Screen All Risk Factors Associated with Alzheimer's Disease Oleg Butovsky, Ph.D., Brigham and Women's Hospital; Harvard Medical School Vijay K. Kuchroo, D.V.M., Ph.D., Brigham and Women's Hospital; Harvard Medical School	\$431,250
Antiviral T Cell Infiltration to the Meninges and Brain Influences Neurodegeneration in Alzheimer's Disease Jasmin Herz, Ph.D., Washington University School of Medicine in St. Louis	\$201,248
Contribution of Skull Bone Marrow-Derived Cells to Alzheimer's Disease Jonathan Kipnis, Ph.D., Washington University School of Medicine in St. Louis	\$201,250
Contributions of IL-34 Signaling to Microglial Function and Alzheimer's Pathology in Mice Staci Bilbo, Ph.D., Duke University School of Medicine	\$195,434
Elucidating the Role of CLEC7A in Tau-Mediated Neurodegenerative Disease John R. Lukens, Ph.D., University of Virginia	\$201,250
Endogenous Human Antibodies Associated with Alzheimer's Disease Charles Glabe, Ph.D., University of California, Irvine	\$230,000
Extracellular ATP is a Key Factor in Promoting Alzheimer's Disease Neuroinflammation Paola Pizzo, Ph.D., University of Padova, Italy Francesco Di Virgilio, M.D., University of Ferrara, Italy	\$150,000
Human Brain CD33 Ligand, Receptor Protein Tyrosine Phosphatase Zeta (RPTP�)S3L, Limits Microglial Phagocytosis and Contributes to Alzheimer's Disease Progression Ronald L. Schnaar, Ph.D., The Johns Hopkins University Philip C. Wong, Ph.D., The Johns Hopkins University	\$201,250
Investigating Bone Marrow Hematopoiesis as the Link Between Sleep Fragmentation and Vascular Inflammation in Alzheimer's Disease Cameron McAlpine, Ph.D., Icahn School of Medicine at Mount Sinai	\$172,500
Investigating MEF2C Transcription Factor as a Therapeutic Target to Reprogram Pathological Microglial States in Alzheimer's Disease Alison M. Goate, D.Phil., Icahn School of Medicine at Mount Sinai Edoardo Marcora, Ph.D., Icahn School of Medicine at Mount Sinai	\$201,250
Mechanisms of Astrocyte-Derived Lipid Toxicity in Alzheimer's Disease Shane A. Liddelow, Ph.D., New York University	\$208,033
Neuroimmune Connectome Perturbations in Alzheimer's Disease Francisco J. Quintana, Ph.D., Brigham and Women's Hospital; Harvard Medical School	\$201,250

2023 FUNDED RESEARCH (CONTINUED)

Project/Researcher	Distribution Amount
Neuroinflammation at the Choroid Plexus in Alzheimer's Disease Maria K. Lehtinen, Ph.D., Boston Children's Hospital; Harvard Medical School Liisa Myllykangas, M.D., Ph.D., University of Helsinki, Finland	\$201,250
Prenatal Inflammation Effects on Blood-Brain Barrier Function and Alzheimer's Disease-Related Pathologies Across the Lifespan Alexandre Bonnin, Ph.D., University of Southern California	\$201,250
Revealing New Genes and Pathways at the Intersection of Lipotoxic and Genetic Risk for Alzheimer's Disease Anna Greka, M.D., Ph.D., Brigham and Women's Hospital; Broad Institute Beth Stevens, Ph.D., Boston Children's Hospital; Harvard Medical School; Broad Institute	\$172,550
Role of CD8+ T-Cell-Glial Interactions in Mediating Alzheimer's Disease Pathogenesis Mehdi Jorfi, Ph.D., Massachusetts General Hospital; Harvard Medical School Joseph Park, Ph.D., Massachusetts General Hospital; Harvard Medical School Rudolph E. Tanzi, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$201,250
Role of Checkpoint Molecules TIM-3 and LAG-3 in Microglial Function in Alzheimer's Disease Vijay K. Kuchroo, D.V.M., Ph.D., Brigham and Women's Hospital; Harvard Medical School	\$201,250
Signaling Function of TREM2 Cleavage Products, Which are Affected by Agonistic Antibodies to the Stalk Region Christian Haass, Ph.D., German Center for Neurodegenerative Diseases (DZNE), Germany Kai Schlepckow, Ph.D., German Center for Neurodegenerative Diseases (DZNE), Germany	\$172,500
T Cell Epigenetics in Alzheimer's Disease David M. Gate, Ph.D., Northwestern University Feinberg School of Medicine	\$172,500
Tau and Amyloid Beta are Innate Immune Antimicrobial Peptides in the Brain William Eimer, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$172,500
The Role of Astrocyte-Secreted Insulin-Like Growth Factor Binding Protein 2 (IGFBP2) in the Progression of Alzheimer's Disease Nicola Allen, Ph.D., Salk Institute for Biological Studies	\$172,500
The Role of Interferon-Induced Transmembrane Protein 3 (IFITM3) and Gamma-Secretase in Microglia Yueming Li, Ph.D., Memorial Sloan Kettering Cancer Center	\$230,000
To Elucidate the Role of Memory T Cells as a Determinant of Age-Related Inflammation in Alzheimer's Disease Susan M. Kaech, Ph.D., Salk Institute for Biological Studies	\$201,250
Understanding the Dynamic Lipid-Immunometabolome of Protective and Risk Alzheimer's Microglia Rik van der Kant, Ph.D., Amsterdam University Medical Center, The Netherlands	\$201,250
Understanding the Role of Natural Amyloid Beta-Specific B Cell Responses in Alzheimer's Disease Progression Marco Colonna, M.D., Washington University School of Medicine in St. Louis	\$172,500
STUDIES OF ALTERNATIVE NEURODEGENERATIVE PATHWAYS	
Brain Entry and Exit Consortium: A 3D In Vitro Neurovascular Human Brain Model with Meningeal Lymphatics for Elucidating Mechanisms Underlying Alzheimer's Disease Se Hoon Choi, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$230,000
Brain Entry and Exit Consortium: Biochemical and Functional Analysis of Cerebrospinal Fluid and Lymph Following Changes in Brain Fluid Dynamics Laura Santambrogio, M.D., Ph.D., Weill Cornell Medicine	\$287,500
Brain Entry and Exit Consortium: Central Nervous System Fluid Homeostasis and Waste Clearance in Alzheimer's Disease Characterized by MRI Helene Benveniste, M.D., Ph.D., Yale School of Medicine Allen R. Tannenbaum, Ph.D., State University of New York at Stony Brook	\$204,081
Brain Entry and Exit Consortium: Crosstalk of Central Nervous System Barriers and Clearance Routes in Homeostasis and Alzheimer's Disease Jonathan Kipnis, Ph.D., Washington University School of Medicine in St. Louis	\$345,000

2023 FUNDED RESEARCH (CONTINUED)

Project/Researcher	Distribution Amount
Brain Entry and Exit Consortium: Identifying the Blood-Brain Barrier Changes During Alzheimer's Disease Richard Daneman, Ph.D., University of California, San Diego	\$287,500
Microbiome Consortium: Harnessing Diet-Microbe Interactions to Prevent Alzheimer's Disease Pathogenesis Laura M. Cox, Ph.D., Brigham and Women's Hospital; Harvard Medical School	\$287,500
Microbiome Consortium: Interaction of the Microbiome with Astrocytes and Amyloid Pathology Robert J. Vassar, Ph.D., Northwestern University Feinberg School of Medicine	\$345,000
Microbiome Consortium: Microbial Profiling of Human Brain and Gut Microbiomes in Alzheimer's Disease Rudolph E. Tanzi, Ph.D., Massachusetts General Hospital; Harvard Medical School Nanda Kumar Navalpur Shanmugam, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$287,500
Microbiome Consortium: Temporal Relationships Between Gut Dysbiosis, Brain Amyloid Beta Metabolism and Microglia Cell Activation Following Antibiotic Treatment Sangram S. Sisodia, Ph.D., University of Chicago	\$250,000
Microbiome Consortium: The Role of Gut Microbial Metabolism in Tau-Mediated Neurodegeneration David M. Holtzman, M.D., Washington University School of Medicine in St. Louis	\$287,500
A Multimodality Study on the Lipid Molecular Basis of Obesity and Its Roles in Regulating Alzheimer's Pathogenesis for Developing Potential Targeted Interventions Stephen T.C. Wong, Ph.D., Houston Methodist Research Institute; Weill Cornell Medicine	\$201,199
Air Pollution and Alzheimer's Disease Risk Interact with Premature Aging of Neural Stem Cells and Apolipoprotein E Alleles Caleb E. Finch, Ph.D., University of Southern California Michael A. Bonaguidi, Ph.D., University of Southern California	\$301,069
Alzheimer's Disease Pathophysiology Alters the Level of Electrical and Chemical Synapse Coupling in the Network of GABAergic PV+ Interneurons Early in Disease Course Srdjan D. Antic, M.D., University of Connecticut Health Center Riqiang Yan, Ph.D., University of Connecticut Health Center	\$230,000
Characterizing Gut Bacteriome-Mycobiome Synergy in Correlation to Amylin-Amyloid Beta Antimicrobial Synergy in Alzheimer's Disease (AD) in AD Mouse Models Deepak Kumar Vijaya Kumar, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$201,250
Circadian Desynchrony, Glial Dysfunction and Alzheimer's Disease Pathogenesis Erik S. Musiek, M.D., Ph.D., Washington University School of Medicine in St. Louis	\$198,994
Deciphering and Restoring Computational Setpoints in Alzheimer's Disease Through Sleep-Enhanced Network Homeostasis Keith B. Hengen, Ph.D., Washington University in St. Louis	\$189,902
Decoding Microbial Products Modulating Alzheimer's Disease—Toward Precision Postbiotics Treatment Eran Elinav, M.D., Ph.D., Weizmann Institute of Science, Israel; DKFZ, Germany	\$201,250
Disentangling the Role of Intracranial Arteriosclerosis in Alzheimer's Disease Daniel Bos, M.D., Ph.D., Erasmus University Medical Center, The Netherlands Meike Vernooij, M.D., Ph.D., Erasmus University Medical Center, The Netherlands Frank J. Wolters, M.D., Ph.D., Erasmus University Medical Center, The Netherlands Geert Jan Biessels, M.D., Ph.D., Erasmus University Medical Center, The Netherlands Julia Neitzel, Ph.D., Harvard T.H. Chan School of Public Health	\$167,207
Effect of APOE Genotype in a Novel Rat Model of Cerebral Amyloid Angiopathy William Van Nostrand, Ph.D., The University of Rhode Island	\$201,250
Evaluating TMEM106B Accumulation in Alzheimer's Disease Leonard Petrucelli, Ph.D., Mayo Clinic, Jacksonville Casey N. Cook, Ph.D., Mayo Clinic, Jacksonville	\$201,250

2023 FUNDED RESEARCH (CONTINUED)

Project/Researcher	Distribution Amount
Functional Changes to Cerebrospinal Fluid Immune Cells Resulting from Bacillus Calmette-Guérin (BCG) Vaccination in Older Adults With and Without Alzheimer's Disease Marc Weinberg, M.D., Ph.D., Massachusetts General Hospital; Harvard Medical School Steven E. Arnold, M.D., Massachusetts General Hospital; Harvard Medical School	\$258,750
In Vivo Models for Golgi Fragmentation and the Molecular Pathogenesis of Alzheimer's Disease Samuel E. Gandy, M.D., Ph.D., Icahn School of Medicine at Mount Sinai Yanzhuang Wang, Ph.D., University of Michigan	\$230,000
Morphological, Electrophysiological and Transcriptional Characterization of Single Neurons from Resilient and Susceptible Models of Human Alzheimer's Disease Catherine Kaczorowski, Ph.D., University of Michigan Shannon Moore, Ph.D., University of Michigan	\$201,250
Neuronal Mechanisms Driving Synapse Loss in Alzheimer's Disease Martin Kampmann, Ph.D., University of California, San Francisco	\$201,250
Neuroprotective Effects of the Exercise Hormone Irisin in Alzheimer's Disease Se Hoon Choi, Ph.D., Massachusetts General Hospital; Harvard Medical School Christiane Wrann, D.V.M, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$345,000
Noncoding Translation Feedback Loop in Alzheimer's Disease Xuebing Wu, Ph.D., Columbia University	\$201,250
Oligodendroglial Dynamics and Myelination in Alzheimer's Disease Erin M. Gibson, Ph.D., Stanford University	\$198,751
Restore Meningeal Lymphatic Drainage to Alleviate White Matter Damage and Cerebral Amyloid Angiopathy in a Model of Alzheimer's Disease Sandro Da Mesquita, Ph.D., Mayo Clinic, Jacksonville	\$201,250
Scaling the Divide in Alzheimer's Disease: An Integrated Molecular, Cellular and Network-Level Study Marc Aurel Busche, M.D., Ph.D., University College London, England Samuel Harris, Ph.D., University College London, England	\$191,624
Stress and Neurovascular-Immune Networks in Alzheimer's Disease Scott J. Russo, Ph.D., Icahn School of Medicine at Mount Sinai Wolfram C. Poller, M.D., Icahn School of Medicine at Mount Sinai	\$172,500
Targeting the Microbiome and Innate Immunity in Alzheimer's Disease Howard L. Weiner, M.D., Brigham and Women's Hospital; Harvard Medical School Laura M. Cox, Ph.D., Brigham and Women's Hospital; Harvard Medical School	\$201,250
Understanding the Mechanism Underlying Vaccination for Alzheimer's Disease Charles L. Greenblatt, M.D., Hebrew University of Jerusalem, Israel Ofer N. Gofrit, M.D., Ph.D., Hebrew University of Jerusalem, Israel Benjamin Y. Klein, M.D., Hebrew University of Jerusalem, Israel	\$115,805
DRUG DISCOVERY	
DRUG SCREENING AND LEAD DRUG EVALUATION PROJECTS	
Identification and Development of CD33 Inhibitors and Pre-RNA Splicing Modulators Subhash Sinha, Ph.D., Weill Cornell Medicine	\$201,250
Validation and Characterization of Compounds Modulating Neuroinflammation and Amyloid Beta Uptake in Microglial Cells Ana Griciuc, Ph.D., Massachusetts General Hospital; Harvard Medical School Luisa Quinti, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$201,250

2023 FUNDED RESEARCH (CONTINUED)

Project/Researcher	Distribution Amount
PRECLINICAL AND CLINICAL DRUG DEVELOPMENT	
PRECLINICAL DRUG DEVELOPMENT	
Characterization of CNS-Penetrant HDAC11-Selective Inhibitors in Alzheimer's Disease Can (Martin) Zhang, M.D., Ph.D., Massachusetts General Hospital; Harvard Medical School Changning Wang, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$201,250
Development of Human cGAS Inhibitors to Treat Alzheimer's Disease Li Gan, Ph.D., Weill Cornell Medicine Subhash Sinha, Ph.D., Weill Cornell Medicine	\$250,000
Interrogating Levetiracetam's Impact on Amyloid Pathology and Presynaptic Proteostasis in Knock-In Mouse Models with Humanized Amyloid Beta Jeffrey Savas, Ph.D., Northwestern University	\$136,827
Role of Stabilization of MAMs and MAM-Associated Palmitoylated APP (MAM-palAPP) in Alzheimer's Disease Raja Bhattacharyya, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$201,250
Targeting Neuroinflammation with Nasal Administration of Anti-CD3 Monoclonal Antibody to Treat Alzheimer's Disease Rafael M. Rezende, Ph.D., Brigham and Women's Hospital; Harvard Medical School	\$201,250
CLINICAL TRIAL DESIGN	
A Proposal to Evaluate the Effect of Bacillus Calmette-Guérin Vaccination on Alzheimer's Disease Development Tamir Ben-Hur, M.D., Ph.D., Hadassah University Medical Center, Israel Herve Bercovier, D.V.M., M.Sc., Hebrew University of Jerusalem, Israel	\$223,100
OTHER	
SCIENTIFIC MEETINGS AND SUPPORT	
General Scientific Support Wilma Wasco, Ph.D., Massachusetts General Hospital; Harvard Medical School	\$95,594
Scientific Meeting Support	\$252,027